Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707686 | 0.86 | PARP10 (0.62) | PARP15PARP10PARP2CYP4F2CYP4A11 | |
| SCHEMBL19405761 | 0.85 | ACACA (0.53) | P4HTMNR1H4 | |
| SCHEMBL31681177 | 0.84 | PARP15 (0.49) | PARP15PARP10PARP2CYP4F2CYP4A11 | |
| SCHEMBL10328684 | 0.84 | PARP10 (0.53) | P4HTMPARP15PARP10PARP2CYP4F2 | |
| SCHEMBL1173221 | 0.83 | MAPK1 (0.51) | PARP15PARP10PARP2CYP4F2CYP4A11 | |
| SCHEMBL2813042 | 0.80 | RAB9A (0.53) | P4HTMMCHR1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL2813045 | 0.80 | RAB9A (0.53) | P4HTMMCHR1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL22583269 | 0.79 | PARP10 (0.50) | PARP15PARP10PARP2CYP4F2CYP4A11 | |
| SCHEMBL20812681 | 0.79 | CNR2 (0.60) | MCHR1 | |
| SCHEMBL12420688 | 0.78 | NFE2L2 (0.52) | P4HTMCYP4F2CYP4A11KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | claimed |
| EP-2758393-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL)-AMIDES AS BACE1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | claimed |
| US-8754075-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-17 | — | — | US | claimed |
| EP-2697208-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-02-19 | — | — | EP | claimed |
| EP-2673278-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | claimed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | claimed |
| US-8476264-B2 | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-07-02 | — | — | US | claimed |
| WO-2013041499-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL)-AMIDES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | claimed |
| US-8404680-B2 | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20130072478-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-21 | — | — | US | claimed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | claimed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | claimed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | claimed |
| WO-2012107371-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | claimed |
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | claimed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| CN-111170938-A | 5, 6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | 豪夫迈·罗氏有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | P4HTM 1069/4885PARP15 1273/4885PARP10 3344/4885 |
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | P4HTM 1357/4885PARP15 1629/4885PARP10 3062/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | P4HTM 958/4885PARP15 1077/4885PARP10 3564/4885 |
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, IAPP | P4HTM 2615/4885PARP15 692/4885PARP10 1315/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | P4HTM 1357/4885PARP15 1629/4885PARP10 3062/4885 |
| US-20130072478-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | P4HTM 1540/4885PARP15 1385/4885PARP10 2766/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | P4HTM 1357/4885PARP15 1629/4885PARP10 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.